Essential role of small bowel capsule endoscopy in reclassification of colonic inflammatory bowel disease type unclassified

Table 3 Clinical characteristics and outcome of the patients with negative small bowel capsule

Case	Sex	Age	Treatment pre-SBCE	Treatment post-SBCE	Diagnostic at follow-up
1	M	45	5ASA	5ASA	IBDU
2	F	15	Prednisolone, 5ASA	5ASA	UC
3	F	27	AZT, 5ASA	AZT	UC
4	F	26	5ASA	5ASA	UC
5	M	31	5ASA	5ASA	IBDU
6	F	34	5ASA	5ASA	IBDU
7	M	21	5ASA	5ASA	IBDU
8	F	22	5ASA	5ASA, AZT	IBDU
9	F	56	5ASA	5ASA	UC
10	F	27	AZT, anti-TNF	AZT, anti-TNF	UC
11	F	30	5ASA	5ASA	UC
12	M	24	5ASA	5ASA	CD
13	M	49	5ASA	5ASA	UC
14	M	43	5ASA	5ASA	UC
15	F	30	5ASA + AZT	Anti-TNF	IBDU
16	M	24	5ASA	5ASA	UC
17	F	20	5ASA	5ASA	UC
18	M	55	5ASA	5ASA	IBDU
19	F	31	5ASA	5ASA, AZT, Anti-TNF	UC
20	F	48	5ASA	5ASA, AZT	IBDU
21	M	64	5ASA	5ASA	UC
22	M	44	No treatment	5ASA	IBDU
23	M	53	5ASA	5ASA	IBDU

5ASA: Mesalamine; anti-TNF: Anti-tumor necrosis factor drug; AZT: Azathioprine; CD: Crohn’s disease; IBDU: Colonic inflammatory bowel disease type unclassified; SBCE: Small bowel capsule endoscopy; UC: Ulcerative colitis.